Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib-Reference-Cited by-同舟云学术

Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib

Published:2018-04-26 Issue:17 Volume:131 Page:1955-1959
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Ghez David¹,Calleja Anne²,Protin Caroline³,Baron Marine⁴,Ledoux Marie-Pierre⁵,Damaj Gandhi⁶,Dupont Mathieu⁷,Dreyfus Brigitte⁸,Ferrant Emmanuelle⁹,Herbaux Charles¹⁰,Laribi Kamel¹¹,Le Calloch Ronan¹²,Malphettes Marion¹³,Paul Franciane¹⁴,Souchet Laetitia⁴,Truchan-Graczyk Malgorzata¹⁵,Delavigne Karen¹⁶,Dartigeas Caroline¹⁷,Ysebaert Loïc³

Affiliation:

1. Département d’Hématologie, Gustave Roussy, Villejuif, France;

2. Service d’Hématologie, Groupe hospitalier l'Archet, Nice, France;

3. Service d'Hématologie, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France;

4. Service d’Hématologie, Hôpital de la Pitié Salpêtrière, Paris, France;

5. Service d'Hématologie et d'Oncologie, Hôpital de Hautepierre, Centre Hospitalier Universitaire Strasbourg, Strasbourg, France;

6. Service d’Hématologie, Centre Hospitalier Régional Universitaire, Caen, France;

7. Service des Maladies Infectieuses, Centre Hospitalier de Saint Malo, Saint Malo, France;

8. Service d’Hématologie, Centre Hospitalier Universitaire, Poitiers, France;

9. Service d’Hématologie, Centre Hospitalier Lyon Sud, Pierre-Bénite, France;

10. Service des Maladies du Sang, Centre Hospitalier Universitaire de Lille, Hôpital Huriez, Lille, France;

11. Service d’Hématologie, Centre Hospitalier du Mans, Le Mans, France;

12. Médecine Interne-Maladies du sang-Maladies Infectieuses, Centre Hospitalier de Cornouaille, Quimper, France;

13. Service d’Immuno-Hématologie, Hôpital Saint Louis, Paris, France;

14. Service d’Hématologie, Hôpital Saint Eloi, CHU Montpellier, Montpellier, France;

15. Service de Médecine, Centre Hospitalier de Saumur, Saumur, France;

16. Service des Maladies Infectieuses, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France; and

17. Service d'Hématologie et Thérapie cellulaire, Hôpital Bretonneau, Centre Hospitalier Universitaire Tours, Tours, France

Abstract

Key Points Ibrutinib may be associated with invasive fungal infections especially IA. Most infections usually occur during the first months of treatment, often in patients with other risk factors for fungal infections.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/131/17/1955/1405910/blood818286.pdf

Reference25 articles.

1. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study;Chanan-Khan;Lancet Oncol,2016

2. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia;Byrd;N Engl J Med,2013

3. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia;Burger;N Engl J Med,2015

4. Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib;Ahn;Blood,2016

5. Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia;Arthurs;Respir Med Case Rep,2017

Cited by 250 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of infections for patient treated with ibrutinib in clinical practice;Frontiers in Oncology;2024-09-10

2. Cancer in People with HIV;Infectious Disease Clinics of North America;2024-09

3. New developments in Aspergillus fumigatus and host reactive oxygen species responses;Current Opinion in Microbiology;2024-08

4. Invasive fungal disease in the immunocompromised host: changing epidemiology, new antifungal therapies, and management challenges;Clinical Microbiology and Infection;2024-08

5. Evaluation of infectious morbidity due to BTK inhibitors in indolent B-cell lymphomas: latest research findings and systematic analysis;Expert Opinion on Pharmacotherapy;2024-07-23